Trial Profile

A Phase III, Randomised, Double-blind, Multi-centre, Parallel Group Study to Compare the Efficacy of Cediranib (AZD2171, RECENTIN) (30 mg) When Added to Gemcitabine and Cisplatin versus the Efficacy of Placebo When Added to Gemcitabine and Cisplatin in Patients with Locally Advanced or Metastatic (Stage IIIb/IV) Non Small Cell Lung Cancer.

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 27 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Jul 2020 This trial is completed in United Kingdom according to European Clinical Trials Database record.
13 Aug 2011 New trial record
10 May 2011 This trial is recruiting in Czech Republic and discontinued in United Kingdom.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com